Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.19
-1.5%
$7.05
$3.54
$8.25
$167.50M0.891,814 shs64,122 shs
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$13.67
-1.2%
$13.38
$10.29
$98.00
$128.37M2.43109,000 shs99,678 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$2.18
-5.6%
$1.82
$0.87
$8.70
$73.18M0.25862,995 shs860,975 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.40
+1.2%
$3.41
$2.23
$4.13
$168.75M1.29413,537 shs395,407 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Journey Medical Corporation stock logo
DERM
Journey Medical
-1.51%+0.56%+13.23%+15.04%+25.48%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-1.16%+7.55%+9.71%-1.65%-71.73%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-5.63%+5.31%+29.76%+50.34%-75.64%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
+1.19%+0.29%0.00%+18.88%-6.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Journey Medical Corporation stock logo
DERM
Journey Medical
2.2803 of 5 stars
3.51.00.00.02.81.70.6
Korro Bio, Inc. stock logo
KRRO
Korro Bio
1.3447 of 5 stars
3.61.00.00.00.60.00.6
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.5604 of 5 stars
3.44.00.00.02.60.00.6
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.2585 of 5 stars
3.52.00.00.02.94.23.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Journey Medical Corporation stock logo
DERM
Journey Medical
3.00
Buy$9.5032.13% Upside
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.29
Buy$102.43649.29% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.80
Moderate Buy$9.60340.37% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00105.88% Upside

Current Analyst Ratings Breakdown

Latest OTLK, DERM, KRRO, and PBYI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $21.00
5/20/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.00
5/8/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$115.00 ➝ $100.00
4/29/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M2.98N/AN/A$0.91 per share7.90
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$2.27M56.55N/AN/A$17.12 per share0.80
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($3.09) per shareN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.73$0.85 per share3.99$1.88 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.390.00N/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$83.58M-$9.440.00N/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.910.00N/AN/AN/AN/A-271.12%8/13/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.428.95N/A16.37%49.35%18.25%7/30/2025 (Estimated)

Latest OTLK, DERM, KRRO, and PBYI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q3 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.42N/AN/AN/A$1.66 millionN/A
8/12/2025Q2 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.54N/AN/AN/A$0.41 millionN/A
8/11/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.06N/AN/AN/A$14.93 millionN/A
8/7/2025Q2 2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.11N/AN/AN/A$52.00 millionN/A
5/15/2025Q2 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/14/2025Q1 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
5/7/2025Q1 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Journey Medical Corporation stock logo
DERM
Journey Medical
1.07
1.34
1.03
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
9.41
9.41
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.72
0.57
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43

Institutional Ownership

CompanyInstitutional Ownership
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
4.60%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.96 millionNo Data
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2033.57 million31.96 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.19 -0.11 (-1.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$7.20 +0.00 (+0.07%)
As of 07/18/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$13.67 -0.16 (-1.16%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$13.72 +0.05 (+0.40%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$2.18 -0.13 (-5.63%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.22 +0.04 (+2.06%)
As of 07/18/2025 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.40 +0.04 (+1.19%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.44 +0.04 (+1.03%)
As of 07/18/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.